|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |

|  |  |
| --- | --- |
|

|  |
| --- |
|  |

 |

 |  |

 |
|

|  |
| --- |
|   |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| http://img.diffusion.social.gouv.fr/5a5873edb85b530da84d23f7/MSv8g1AWR2u-sDNggvKhqw/VzwFhdTCT1SMy7TUnHtCzw-Marianne.png |

 |

 |

 |

|  |
| --- |
|  |

 |

 |

 |  |

 |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **COMMUNIQUE DE PRESSE** |

 |

 |

 |

 |  |

 |
|

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Paris, le 10 décembre 2021 |

 |

 |

 |

 |  |

 |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **Molnupiravir : le ministère des Solidarités et de la Santé prend acte de la décision de la Haute Autorité de Santé (HAS)** |

 |

 |

 |

 |  |

 |
|

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Depuis le début de la crise sanitaire, la France anticipe l’arrivée de nouveaux traitements contre le Covid-19 pour permettre, en cas d’autorisations des autorités sanitaires, des déploiements rapides et sécurisés.Le ministère des Solidarités et de la Santé a pris acte de la décision de la HAS du 9 décembre 2021 concernant la mise à disposition de LAGEVRIO® en accès précoce en France pour les traitements des patients symptomatiques à risque de faire des formes graves de Covid-19. La HAS a estimé, qu’à date, l’ensemble des critères permettant d’octroyer un accès précoce ne sont pas atteints.La nature du contrat prévoit un déclenchement des commandes uniquement en cas d’autorisation précoce de déploiement. Les échanges avec l’agence européenne du médicament (EMA) continuent et une décision européenne concernant la demande d’autorisation de mise sur le marché est attendue début d’année 2022.D’autres traitements sont en cours de développement et pourront être évalués au cours des prochaines semaines. Le vaccin et l’utilisation d’alternatives thérapeutiques sont des modalités complémentaires de lutte contre le Covid-19. Pour rappel, la vaccination est une mesure de prévention qui protège efficacement contre les formes graves de la maladie : c’est le meilleur moyen aujourd’hui pour éviter une hospitalisation et l’évolution d’une contamination par la COVID-19 vers une forme grave de la maladie. |

 |

 |

 |

 |  |

 |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| **Contact presse :****presse-dgs@sante.gouv.fr** |

 |

 |

 |

 |  |

|  |
| --- |
|   |

 |
|

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |  |  |
| --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
| Si vous ne souhaitez plus recevoir nos communications, [suivez ce lien](https://eye.diffusion.social.gouv.fr/v3/r/USBSHOW/84/5a5873edb85b530da84d23f7/MSv8g1AWR2u-sDNggvKhqw/VzwFhdTCT1SMy7TUnHtCzw/6123af465e060f44e45d0bcc?email=presse-dgs@sante.gouv.fr&adm=sarbacane@sg.social.gouv.fr) |

 |

 |

 |

 |  |

 |

 |

 |

 